SOTIO takes up option on Synaffix ADCs

Prague headquartered clinical-stage firm SOTIO Biotech, which is owned by the Czech Republic's PPF Group, today announced it will be exercising its option, under its license and option agreement with Synaffix, a Lonza company (SWX: LONN), to obtain a license to Synaffix’s technology to develop two bispecific antibody-drug conjugate (ADC) programs.

The two companies first entered into a collaboration in 2023, and the exercised option will enable SOTIO to advance two bispecific candidates, designed by its in-house research team, that have the potential to become first-in-class and/or best-in-class treatments for solid tumors. SOT112 is a bispecific ADC with potential applicability in several major cancer indications, while SOT113 demonstrates promise for precision targeting of prostate cancer. Both programs leverage the selection of highly attractive target pairs and are now in the lead nomination stage.

The bispecific antibody candidates were identified by SOTIO’s research team and will now be developed under SOTIO’s license and option agreement with Synaffix, which enables SOTIO to combine its proprietary antibodies with Synaffix’s GlycoConnect, HydraSpace, and potent linker-payloads of the toxSYN platform to research, develop, manufacture, and commercialize ADC products.